908 Devices earnings release, May 6, 2026

908 Devices Inc. (MASS) · Form 8-K, Item 2.02 · Filed · SEC filing

908 Devices Reports First Quarter 2026 Financial

Results and Raises 2026 Revenue Outlook

Revenue increased 14% compared to prior year, growth in both Mass Spec and FTIR

Acquired NIRLAB AG, expanding narcotics identification capabilities

BURLINGTON,

Mass. – May 6, 2026 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026.

“We delivered a strong start to 2026, achieving

14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strategic transaction that broadens our reach into the lower-cost, widely-deployable segment of the narcotics detection market while increasing our recurring revenue opportunity through software subscriptions. This transaction reflects our focus on disciplined growth investments as we continue to execute our transformation strategy.”

Recent Highlights

First Quarter 2026 Financial Results

Revenue was $13.4 million for the three months ended March 31, 2026, a 14% increase over the prior year period, driven by an increase in product revenue for mass spec, from an increase in placements, and from a shift in FTIR product mix. OEM and funded partnership revenue was $0.6 million for the current and prior year period. The installed base grew 23% year-over-year to 3,903 devices, with 167 devices placed during the first quarter. Recurring revenue represented 30% of total revenues in the quarter.

Gross profit was $6.9 million for the first quarter of 2026, compared to $5.5 million for the corresponding period in the prior year. GAAP gross margin was 51% as compared to 47% for the corresponding prior year period. Adjusted gross profit was $7.7 million for the first quarter of 2026, compared to $6.4 million for the corresponding period in the prior year. Adjusted gross margin was 57%, as compared to 54% for the corresponding prior year period. The increase in adjusted gross margin percentage was primarily driven by higher product revenues, including a shift in channel mix, along with the favorable impact of consolidated facilities, offset in part by lower service gross margins.

Operating expenses were $19.8 million for the first quarter of 2026, compared to $16.6 million for the corresponding prior year period. The increase of $3.2 million includes a noncash increase of $3.9 million related to a change in the fair value of the contingent consideration liability, and a $0.7 million reduction of operating expenses related to research and development and selling, general, and administrative costs.

Net loss from continuing operations was $12.0 million for the first quarter of 2026, compared to a net loss from continuing operations of $9.8 million for the corresponding prior year period. Adjusted EBITDA was a loss of $2.5 million for the first quarter of 2026, compared to a loss of $4.6 million for the corresponding period in the prior year.

Net loss attributable to common stockholders was $12.0 million for the first quarter of 2026, compared to net income of $43.6 million for the corresponding prior year period. The income was related to the divestiture of our bioprocessing product portfolio which resulted in a gain of $56.6 million, net of transaction costs, and was also offset by a loss from discontinued operations for the first two months of the first quarter of 2025.

Cash, cash equivalents and marketable securities were $111.7 million as of March 31, 2026, with no debt outstanding.

2026 Guidance

908 Devices now expects full year 2026 revenues to be in the range of $67.0 million to $70.0 million, representing 19% to 25% growth compared to 2025 revenue.

Webcast Information

908 Devices will host a conference call to discuss the first quarter

2026 financial results before market open on Wednesday, May 6, 2026 at 8:30 am Eastern Time. A webcast of the conference call can be accessed in the Investor Relations section of 908devices.com. The webcast will be archived and available for replay for at least 90 days after the event.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.

Non-GAAP Measures of Financial Performance

To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable

GAAP financial results in the tables below:

The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However,... (truncated)GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results.

Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of

Financial statements

Income Statement

Three Months Ended March 31, — (unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Revenue:Product revenue10,7378,529
Revenue:Service and contract revenue2,6443,248
Revenue:Total revenue13,38111,777
Cost of revenue:Product cost of revenue5,1604,725
Cost of revenue:Service and contract cost of revenue1,3391,511
Cost of revenue:Total cost of revenue6,4996,236
Cost of revenue:Gross profit6,8825,541
Operating expenses:Research and development3,4713,829
Operating expenses:Selling, general and administrative9,91410,239
Operating expenses:Change in fair value of contingent consideration6,3812,499
Operating expenses:Total operating expenses19,75616,567
Operating expenses:Loss from continuing operations-12,884-11,026
Operating expenses:Other income, net9291,189
Operating expenses:Net loss from continuing operations-11,955-9,837
Operating expenses:Net income from discontinued operations, net of tax53,440
Operating expenses:Net income (loss) attributable to common stockholders-11,95543,603
Operating expenses:Net income (loss) from continuing operations per share attributable to common stockholders, basic and diluted-0.32-0.28
Operating expenses:Net income from discontinued operations per share attributable to common stockholders, basic and diluted$—1.51
Operating expenses:Net income (loss) per share attributable to common stockholders, basic and diluted-0.321.23
Operating expenses:Basic and diluted36,818,48135,386,483

Income Statement

Three Months Ended — Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage: (in thousands)

Three Months Ended – March 31, – 2026Three Months Ended – March 31, – 2025
Gross Profit (GAAP)6,8815,541
Intangible amortization635635
Acquisition and integration costs50
Restructuring66
Stock-based compensation155117
Adjusted Gross Profit (Non-GAAP)7,6716,409
Gross Margin Percentage (GAAP)51.0%47
Adjusted Gross Margin Percentage (Non-GAAP)57.0%54

Balance Sheet

December 31, — (unaudited) (in thousands)

March 31, – 2026December 31, – 2025
Current assets:Cash, cash equivalents and marketable securities111,742112,970
Current assets:Accounts receivable, net9,86511,327
Current assets:Inventory13,24012,990
Current assets:Prepaid expenses and other current assets7,1677,272
Current assets:Total current assets142,014144,559
Current assets:Operating lease, right-of-use assets4,2054,397
Current assets:Property and equipment, net4,1414,232
Current assets:Intangible, net35,67936,412
Current assets:Other long-term assets656471
Current assets:Total assets186,695190,071
Current liabilities:Accounts payable and accrued expenses7,0848,424
Current liabilities:Deferred revenue9,4708,934
Current liabilities:Operating lease liabilities and other liabilities23,10616,706
Current liabilities:Total current liabilities39,66034,064
Current liabilities:Deferred revenue, net of current portion9,0688,331
Current liabilities:Other long-term liabilities3,7963,977
Current liabilities:Total liabilities52,52446,372
Current liabilities:Total stockholders' equity134,171143,699
Current liabilities:Total liabilities and stockholders' equity186,695190,071
Full release

1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth and the benefits of the Company’s acquisition of NIRLAB. Words such as

“may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission (SEC) which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC.

Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Investor and Media Contact:

Barbara Russo

IR@908devices.com

908 DEVICES INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

908 DEVICES INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

908 DEVICES INC.

Reconciliations of GAAP to Non-GAAP Financial

Measures

(Unaudited, amounts in thousands, except percentage and per share data)

In all tables below, totals may not add due to rounding

Reconciliation from Gross Profit (GAAP) to

Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

Reconciliation from Net Loss from Continuing

Operations (GAAP) to Adjusted EBITDA (Non-GAAP):

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · 908 Devices earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.